Compare BMBL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | ABUS |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.9M | 836.0M |
| IPO Year | 2021 | 2008 |
| Metric | BMBL | ABUS |
|---|---|---|
| Price | $5.94 | $4.21 |
| Analyst Decision | Hold | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $4.05 | N/A |
| AVG Volume (30 Days) | ★ 10.5M | 6.1M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | ★ $965,658,000.00 | $14,083,000.00 |
| Revenue This Year | N/A | $1,208.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.99 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $2.44 | $3.50 |
| 52 Week High | $5.98 | $5.45 |
| Indicator | BMBL | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 89.17 | 37.35 |
| Support Level | $2.66 | $4.17 |
| Resistance Level | N/A | $4.57 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.26 | 0.00 |
| Stochastic Oscillator | 98.87 | 17.33 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.